CJC-1295 and Ipamorelin Are Pharmacologically Distinct Peptides
CJC-1295 and Ipamorelin are often mentioned together since both have been studied in relation to growth hormone (GH) secretion. However, they act upon the GH axis by different pharmacological methods.
CJC-1295 is a long-acting analogue of growth hormone-releasing hormone (GHRH) and its activity therefore takes place via the GHRH receptor pathway. Research has looked into its effects on the secretion of GH, on insulin-like growth factor 1 (IGF-1), and on pharmacokinetic persistence.
Ipamorelin falls within a separate class and was considered a selective agent able to stimulate the release of growth hormone via the GHRP-like receptor system, a system which is now linked to the growth hormone secretagogue receptor, GHS-R1a. Early pharmacological studies showed that the effect of ipamorelin in stimulating the release of growth hormone was different from the effect obtained by direct stimulation of the GHRH receptor.
It is important when carrying out comparative research to keep this distinction in mind since the fact that the compounds produce similar effects at the downstream level does not indicate that they act through the same molecular mechanism.
CJC-1295 and Ipamorelin Target Different Signalling Pathways
CJC-1295 and the GHRH Receptor
GHRH is a peptide which is produced in the hypothalamus and has a role in the regulation of the secretion of growth hormone from the anterior pituitary; CJC-1295 is a modified form of GHRH that has much greater persistence and duration than native GHRH.
Experimental research found that CJC-1295 is a modified version of the human GHRH(1-29), the modification allowing it to bind to albumin; since it can bind to albumin the drug remains in the circulation for a longer time than the native peptide which has a shorter duration of action.
From a signalling perspective, it is important that CJC-1295 exerts its effects via the GHRH receptor pathway not by directly acting as an agonist at the ghrelin receptor.
Since the study is being conducted for research purposes, receptor identity should be taken into consideration when comparing CJC-1295 with other GH-axis peptides.
Ipamorelin and GHS-R1a Signalling
Ipamorelin is a synthetic pentapeptide which has GH-secretagogue properties, and early pharmacological studies indicated that its capacity to release GH resulted from its effect on a GHRP-like receptor rather than via the GHRH pathway.
The receptor which at present is linked to this type of activity is GHS-R1a, the growth hormone secretagogue receptor.
Consequently, Ipamorelin has a definite role in the GH regulatory network since, unlike a GHRH analogue, it is a member of the secretagogue group of compounds that are used in the study of GHS-R-mediated signalling.
Why Receptor Identity Matters in Comparative Research
A comparison that takes into account only the measured concentrations of GH may conceal important differences in mechanism.
Two experimental compounds may affect the same downstream biomarker even if the receptors to which they bind are situated further upstream.
A useful comparison therefore separates: Primary receptor or signalling target, Molecular class, Duration of exposure, Pharmacokinetic profile, Timing of biomarker sampling, Experimental model, Measured endpoint
It is especially important to keep this difference in mind when comparing results from different studies. A GH concentration measured at one moment is not the same as a concentration measured with a different experimental design.
Pharmacokinetic Differences Between CJC-1295 and Ipamorelin
The way in which the two compounds are dealt with by the body is clearly different.
Research published on CJC-1295 indicates that the drug remains in the body for a long time. In a study with healthy adults the estimated half-life was between 5.8 and 8.1 days and the changes in GH and IGF-1 levels continued beyond the time at which the samples were taken.
Previous preclinical studies also discovered that CJC-1295 remained detectable in the plasma for a long time and exhibited greater stability than the parent GHRH fragment which had been used for comparison.
Ipamorelin has a quite different pharmacokinetic profile; a pharmacokinetic–pharmacodynamic study carried out in healthy volunteers showed that it had a short terminal half-life of approximately two hours and that growth hormone stimulation took place over a relatively short time course.
The existence of differences carries practical implications for the way that laboratory studies are designed.
It is not appropriate to apply the same sampling assumptions to a peptide which has a short duration of action as you do to a long-acting analogue since the interpretation of the experimental results is affected by sampling windows, baseline measurements, the observation periods, and pharmacokinetic modelling.
GH and IGF-1 as Research Endpoints
GH and IGF-1 are usually measured whenever one is looking at substanthat interact with the the GH regulatory system.
Yet the biomarkers should be kept separate from any remarks made about downstream physiological or clinical outcomes.
For instance, a study that examined the levels of plasma GH and IGF-1 in healthy adults discovered that the changes stayed behind after exposure.
The fact that this finding was observed relates solely to the endocrine endpoints which were measured and does not by itself show any changes in muscle mass, athletic performance, body composition, recovery, or some other functional result.
This distinction is especially important when comparing peptide research because GH and IGF-1 measurements can be influenced by: sampling time, baseline endocrine state, experimental model, assay methodology, duration of observation, pharmacokinetic exposure, endogenous hormone pulsatility
Consequently, the biomarker data has to be interpreted in the experimental conditions in which they were obtained.
Pharmacokinetics Can Change How Experimental Results Are Interpreted
The fact that CJC-1295 and Ipamorelin have different persistence profiles represents a major methodological difference.
A drug which has a shorter duration of action can produce a more specific pharmacodynamic response. On the other hand, one which has a long duration of action leads to a longer exposure period, causing the relationship between concentration, receptor activity, and the downstream biomarkers to become more temporally complicated.
This point is especially pertinent to GH since endogenous secretion is naturally pulsatile.
Research has looked into whether GH pulsatility can still be detected when stimulation is continuous; in a study performed on humans it was found that GH secretion stayed pulsatile even though the trough and mean GH concentrations increased.
The evidence for this is that a single measurement of GH is not sufficient to fully describe the entire endocrine response.
For laboratory researchers, the time interval between exposure and sampling is just as important as the absolute concentration which is measured.
Why CJC-1295 and Ipamorelin Studies Should Not Be Treated as Direct Comparative Evidence
A frequent issue with online comparisons is to bring together the results of different studies and then regard them as if they had come from the same experiment.
For instance, a study on CJC-1295 could involve one particular population, one analytical method, one sampling schedule, and one endpoint, whereas a study on ipamorelin could use entirely different conditions.
It is not valid to suppose that the differences between the various studies are due to the peptides themselves.
A scientifically meaningful comparison should account for:
Experimental Model
The results obtained from cells grown in the laboratory, from rodents, from non-human primates, and from humans arise in different biological settings
Endpoint Selection
GH concentration, IGF-1 concentration, receptor activation, gene expression, and pharmacokinetic measurements each answer different research questions.
Sampling Schedule
If the samples are taken outside the relevant time window then a short-duration response will be missed or underappreciated.
Compound Identity
The term linked with CJC-1295 could also be misleading since, although CJC-1295 is associated with the long-acting modified GHRH analogue, other research materials might refer to different peptide preparations as modified GRF(1-29). Therefore, the names should not be regarded as interchangeable.
What the Research Can and Cannot Establish
The evidence contained in the published literature shows that CJC-1295 and Ipamorelin have different effects on the regulation of GH and differs markedly in their pharmacokinetic properties.
It is wrong to draw unsupported conclusions from this data regarding the treatment's effectiveness, physical performance, body composition, or any other outcomes which were not directly measured.
The results of the endocrine studies in humans should also not be taken as evidence that either of the compounds is suitable for self-administration.
When researchers are working on a particular subject the most useful question to ask is not which compound is "better", but instead which molecular pathway and experimental feature are relevant to the research question in question.
Using Peptide Research Data More Precisely
Before comparing CJC-1295 and Ipamorelin, the researchers first had to decide which variable they actually wanted to look at.
It is necessary when studying receptors to differentiate between signalling via the GHRH receptor and that via the GHS-R1a.
In pharmacokinetic studies the duration of human exposure and the intervals between the times when samples are collected become more important.
Attention should be paid when endocrine biomarkers are under investigation to the pulsatility of GH, the IGF-1 measurements, the baseline values, and the timing of the assays in relation to the compound under investigation.
This approach does not consider two peptides which have different pharmacological properties to be merely different forms of the same research substance.
If anyone requires any more information on peptides, they should go to the relevant peptide category and then look in turn at each compound's technical documentation, analytical information, and research-use specifications.
Research Use Only
The information given on this page about CJC-1295 and Ipamorelin is provided entirely for use in laboratory and scientific research.
The information given above concerns research that has been published in the areas of pharmacology, receptor biology, pharmacokinetics, and experimental results; it is not to be regarded as medical advice and must not be treated as a suggestion for use in humans or as containing any instructions about administration, dosage, treatment, or the management of disease.
The research findings that involve GH or IGF-1 biomarkers should not be interpreted as indicating a therapeutic or performance-related effect.
FAQs
References
- 1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PubMed ↗
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PubMed ↗
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999 Sep;16(9):1412-6. doi: 10.1023/a:1018955126402. PubMed ↗
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PubMed ↗
- Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8. doi: 10.1210/en.2004-1286. Epub 2005 Apr 7. PubMed ↗
